Drug:
Reaction: PRODUCT USE ISSUE
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25097664 |
US |
1 | |
Product use issue, Product distribution issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 302 | 25097729 |
US |
59 | 2 |
Sinusitis, Urinary tract infection, Hypersomnia, Seasonal allergy, Fungal infection, Multiple allergies, Back pain, Infusion site haemorrhage, Headache, Fatigue, Diarrhoea, Myalgia, Dyspnoea, Dizziness, Upper respiratory tract infection, COVID-19, Illness, Insurance issue, Product use issue, |
||||
PREDNISONE, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, FUROSEMIDE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, ALBUTEROL SULFATE, EPINEPHRINE, ADRENALINUM, FLUTICASONE PROPIONATE, AMLODIPINE BESYLATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, AMITRIPTYLINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, VALSARTAN, TIZANIDINE HYDROCHLORIDE, LIDOCAINE, |
||||
| 303 | 25097752 |
CA |
2 | |
Exposure during pregnancy, Food allergy, Immunodeficiency, Infusion related reaction, Intentional product misuse, Joint swelling, Off label use, Overdose, Pain, Prescribed overdose, Product use issue, Hyperhidrosis, Hepatic enzyme increased, Hypersensitivity, Headache, Hypertension, |
||||
VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, ALBUTEROL SULFATE, ALBUTEROL, TOCILIZUMAB, ALBUTEROL SULFATE, SENNA LEAF, TOCILIZUMAB, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 304 | 25097860 |
BE |
2 | |
Somnolence, Vomiting, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 305 | 25097930 |
CN |
74 | 2 |
Product use issue, |
||||
MOLNUPIRAVIR, MEROPENEM, VORICONAZOLE, |
||||
| 306 | 25098010 |
US |
77 | 2 |
Carpal tunnel syndrome, Illness, Product use issue, |
||||
SEMAGLUTIDE, SEMAGLUTIDE, INSULIN GLARGINE, |
||||
| 307 | 25098047 |
US |
2 | |
Insurance issue, Product use issue, |
||||
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, |
||||
| 308 | 25098079 |
FR |
31 | 2 |
Pregnancy with implant contraceptive, Unintended pregnancy, Product use issue, Inappropriate schedule of product administration, |
||||
ETONOGESTREL, |
||||
| 309 | 25098293 |
SE |
2 | |
Pregnancy with implant contraceptive, Unintended pregnancy, Complication of device removal, Product use issue, |
||||
ETONOGESTREL, RIZATRIPTAN BENZOATE, PREGABALIN, SERTRALINE, BUDESONIDE, |
||||
| 310 | 25098408 |
US |
73 | 2 |
Product use issue, Off label use, |
||||
LENALIDOMIDE, |
||||
| 311 | 25098455 |
CA |
70 | 2 |
Prescribed underdose, Product use issue, Rectal haemorrhage, Underdose, Constipation, |
||||
METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, RAMIPRIL, NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, CALCIUM, PANTOPRAZOLE, PREGABALIN, ROSUVASTATIN, |
||||
| 312 | 25098609 |
FR |
13 | 1 |
Off label use, Vomiting, Hypogammaglobulinaemia, Off label use, Blood immunoglobulin G decreased, Product use issue, Product use issue, |
||||
DARATUMUMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, OBINUTUZUMAB, METHYLPREDNISOLONE, METHYLPREDNISOLONE, PREDNISONE, PREDNISONE, PREDNISONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, OFATUMUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 313 | 25098651 |
US |
||
Product use issue, |
||||
BOSENTAN, |
||||
| 314 | 25098723 |
US |
76 | 1 |
Pain, Product use issue, |
||||
CAPSAICIN, |
||||
| 315 | 25099584 |
BE |
||
Somnolence, Vomiting, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 316 | 25099646 |
US |
70 | 1 |
Insurance issue, Malaise, Therapy interrupted, Product use issue, |
||||
ABATACEPT, |
||||
| 317 | 25099865 |
ZA |
71 | |
Chest discomfort, Product use issue, |
||||
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, FUROSEMIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, METRONIDAZOLE, METRONIDAZOLE TOPICAL, |
||||
| 318 | 25099894 |
US |
1 | |
Seizure, Product use issue, |
||||
PERAMPANEL, |
||||
| 319 | 25100097 |
US |
76 | 2 |
Psoriasis, Product use issue, |
||||
DEUCRAVACITINIB, |
||||
| 320 | 25100153 |
CA |
2 | |
Abdominal discomfort, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Arthropathy, Blister, Condition aggravated, Confusional state, Contusion, Discomfort, Duodenal ulcer perforation, Dyspnoea, Folliculitis, General physical health deterioration, Glossodynia, Hand deformity, Helicobacter infection, Ill-defined disorder, Impaired healing, Infection, Infusion related reaction, Injury, Pericarditis, Rheumatoid arthritis, Systemic lupus erythematosus, Gastrointestinal disorder, Arthralgia, Hepatic enzyme increased, Fatigue, Hypersensitivity, Pain, Pemphigus, Maternal exposure during pregnancy, Contraindicated product administered, Product use issue, |
||||
CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CERTOLIZUMAB PEGOL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ALENDRONATE SODIUM, LEFLUNOMIDE, LEFLUNOMIDE, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, APREPITANT, FOSAPREPITANT DIMEGLUMINE, FOLIC ACID, FOLIC ACID, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE SULFATE, SARILUMAB, METHOTREXATE, METHOTREXATE SODIUM, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, SULFASALAZINE, SULFASALAZINE, METHOTREXATE, METHOTREXATE SODIUM, TOCILIZUMAB, ETANERCEPT, ALENDRONATE SODIUM, ADALIMUMAB, ADALIMUMAB-ADAZ, METHOTREXATE, METHOTREXATE SODIUM, ABATACEPT, HYDROXYCHLOROQUINE SULFATE, RITUXIMAB, RITUXIMAB, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, GOLIMUMAB, TOCILIZUMAB, |
||||
| 321 | 25100448 |
US |
57 | 2 |
Off label use, Product use issue, |
||||
PALBOCICLIB, PALBOCICLIB, |
||||
| 322 | 25100451 |
US |
48 | 2 |
Malignant neoplasm progression, Product use issue, Off label use, |
||||
TUCATINIB, CAPECITABINE, |
||||
| 323 | 25100649 |
US |
||
Joint stiffness, Arthralgia, Product use issue, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 324 | 25100731 |
FR |
||
Brachial artery entrapment syndrome, Product use issue, Local reaction, Drug dependence, |
||||
| 325 | 25100851 |
US |
61 | 2 |
Food poisoning, Product use issue, |
||||
| 326 | 25100975 |
AU |
1 | |
Colorectal cancer metastatic, Product use issue, |
||||
FRUQUINTINIB, |
||||
| 327 | 25101093 |
US |
1 | |
Pneumonia, Immunoglobulins decreased, Product dose omission issue, Device malfunction, Sinusitis, Inability to afford medication, Insurance issue, Product use issue, Incorrect dose administered, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, INSULIN DETEMIR, NABUMETONE, NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, IBUPROFEN TABLET COATED, |
||||
| 328 | 25101217 |
US |
||
Drug ineffective, Product use issue, |
||||
C1 ESTERASE INHIBITOR RECOMBINANT, EPINEPHRINE, ADRENALINUM, MONTELUKAST SODIUM, MONTELUKAST, OMALIZUMAB, LORATADINE, LORATADINE ORAL, CETIRIZINE HYDROCHLORIDE, |
||||
| 329 | 25101509 |
BE |
||
Allodynia, Skin burning sensation, Pain of skin, Product use issue, |
||||
FOSFOMYCIN TROMETHAMINE, GRANULES FOR ORAL SOLUTION, GABAPENTIN, |
||||
| 330 | 25101725 |
PL |
55 | 2 |
Retinal detachment, Product use issue, Off label use, |
||||
ENCORAFENIB, BINIMETINIB, NEBIVOLOL HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE, PREGABALIN, PEMBROLIZUMAB, |
||||
| 331 | 25101748 |
US |
57 | 2 |
Norovirus infection, Vomiting, Insurance issue, Product use issue, Product supply issue, Product dose omission issue, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, |
||||
| 332 | 25101752 |
US |
||
Illness, Product use issue, Off label use, |
||||
PANTOPRAZOLE, |
||||
| 333 | 25101774 |
JP |
78 | 2 |
Liver disorder, COVID-19, Myelosuppression, Platelet count decreased, Neutrophil count decreased, Product use issue, |
||||
REGORAFENIB, REGORAFENIB, AMLODIPINE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, SOLIFENACIN SUCCIATE, SOLIFENACIN SUCCINATE, VIBEGRON, |
||||
| 334 | 25101870 |
US |
7 | 2 |
Product dose omission issue, Product use issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 335 | 25101975 |
CN |
67 | 1 |
Hypoglycaemia, Product use issue, |
||||
LINAGLIPTIN, REPAGLINIDE, INSULIN HUMAN, |
||||
| 336 | 25102192 |
US |
77 | 1 |
Right ventricular dysfunction, Systolic anterior motion of mitral valve, Condition aggravated, Mitral valve incompetence, Atrial fibrillation, Left ventricular dysfunction, Decreased ventricular preload, Cardiac amyloidosis, Hypotension, Product use issue, |
||||
NITRIC OXIDE, NITRIC OXIDE, |
||||
| 337 | 25102193 |
US |
53 | 1 |
Right ventricular failure, Cardiac ventricular thrombosis, Acidosis, Vasoplegia syndrome, Product use issue, |
||||
NITRIC OXIDE, NOREPINEPHRINE (BITARTRATE), NOREPINEPHRINE, NOREPINEPHRINE BITARTRATE, VASOPRESSIN, EPINEPHRINE, ADRENALINUM, |
||||
| 338 | 25102197 |
US |
16 | 1 |
Lung transplant, Hypovolaemia, Right ventricular dysfunction, Drug ineffective, Product use issue, |
||||
NITRIC OXIDE, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, FENTANYL, PROPOFOL, |
||||
| 339 | 25102258 |
BG |
70 | 2 |
Mitral valve incompetence, Anaemia, Dyspnoea, Cough, Fatigue, Product use issue, Pleural disorder, |
||||
PEMBROLIZUMAB, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 340 | 25102271 |
ZA |
2 | |
Pregnancy with implant contraceptive, Unintended pregnancy, Female sterilisation, Complication associated with device, Labelled drug-drug interaction issue, Product use issue, |
||||
ETONOGESTREL, |
||||
| 341 | 25102359 |
US |
53 | 2 |
Joint swelling, Arthralgia, Product use issue, |
||||
ABATACEPT, |
||||
| 342 | 25102407 |
SD |
8 | |
Death, Product use issue, |
||||
VELAGLUCERASE ALFA, |
||||
| 343 | 25102432 |
US |
70 | 2 |
Injection site bruising, Product use issue, |
||||
FREMANEZUMAB-VFRM, |
||||
| 344 | 25092114 |
FR |
||
Arrhythmia, Heart rate increased, Rhinorrhoea, Sneezing, Product use issue, Intentional product misuse, |
||||
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 345 | 25092120 |
HU |
56 | 2 |
Death, Product use issue, Off label use, Pneumonia fungal, Pancytopenia, Pseudomonas infection, Febrile neutropenia, |
||||
VENETOCLAX, CLADRIBINE, GILTERITINIB, CYTARABINE, |
||||
| 346 | 25092135 |
US |
52 | 1 |
Product use issue, |
||||
LENALIDOMIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, PIOGLITAZONE, PRAVASTATIN SODIUM, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, GABAPENTIN, FAMOTIDINE, ENALAPRIL MALEATE, ENALAPRIL, |
||||
| 347 | 25092140 |
US |
2 | |
Pyrexia, Condition aggravated, Illness, Product use issue, Off label use, |
||||
CANAKINUMAB, CANAKINUMAB, CANAKINUMAB, |
||||
| 348 | 25092225 |
US |
||
Renal disorder, Product use issue, |
||||
ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, |
||||
| 349 | 25092264 |
US |
48 | |
Product use issue, |
||||
APIXABAN, |
||||
| 350 | 25092313 |
US |
||
Product use issue, |
||||
BOSENTAN, |
||||
| 351 | 25092314 |
US |
||
Product use issue, |
||||
BOSENTAN, |
||||
| 352 | 25092380 |
US |
41 | 2 |
Product use issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 353 | 25092384 |
US |
30 | 2 |
Product dose omission issue, Injection site haemorrhage, Injection site bruising, Injection site pain, Fibromyalgia, Ehlers-Danlos syndrome, Device deployment issue, Memory impairment, Product use issue, |
||||
OMALIZUMAB, OMALIZUMAB, MONTELUKAST SODIUM, LISDEXAMFETAMINE DIMESYLATE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, FAMOTIDINE, RIZATRIPTAN BENZOATE, VALACYCLOVIR HYDROCHLORIDE, |
||||
| 354 | 25092396 |
US |
||
Drug dose omission by device, Device delivery system issue, Oral candidiasis, Product use issue, Product dose omission issue, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 355 | 25092447 |
US |
30 | 2 |
Hereditary angioedema, Hereditary angioedema, Hereditary angioedema, Hereditary angioedema, Hereditary angioedema, Hereditary angioedema, Product use issue, |
||||
| 356 | 25092484 |
US |
94 | 2 |
Product use issue, |
||||
APIXABAN, |
||||
| 357 | 25092642 |
US |
2 | |
Product use issue, Drug ineffective, |
||||
PIMAVANSERIN TARTRATE, LORATADINE, LORATADINE TABLET, |
||||
| 358 | 25092646 |
US |
2 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 359 | 25092782 |
DE |
7 | 2 |
Drug hypersensitivity, Hypersensitivity, Drug ineffective, Condition aggravated, Product use issue, |
||||
VORICONAZOLE, VORICONAZOLE, VORICONAZOLE, AMPHOTERICIN B, AMPHOTERICIN B, AMPHOTERICIN B, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE, |
||||
| 360 | 25092788 |
US |
2 | |
Gastroenteritis viral, Product use issue, |
||||
SEMAGLUTIDE, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, CARBAMAZEPINE, CEPHALEXIN, HYDROCHLOROTHIAZIDE, CARBAMAZEPINE, EPINEPHRINE, ADRENALINUM, CARBAMAZEPINE, ICATIBANT ACETATE, RANITIDINE HYDROCHLORIDE, ALBUTEROL SULFATE, RIVAROXABAN, |
||||
| 361 | 25092851 |
US |
65 | 2 |
Therapeutic product effect variable, Wrong technique in product usage process, Inappropriate schedule of product administration, Product use issue, |
||||
ALPRAZOLAM, ALPRAZOLAM, |
||||
| 362 | 25092896 |
US |
1 | |
Open angle glaucoma, Product use in unapproved indication, Product use issue, |
||||
SEMAGLUTIDE, |
||||
| 363 | 25092909 |
US |
59 | 2 |
Colectomy, Colectomy, Rectal haemorrhage, Hallucination, Nightmare, Weight increased, Dehydration, Ileus, Vomiting, Nausea, Off label use, Product use issue, |
||||
SEMAGLUTIDE, SEMAGLUTIDE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, |
||||
| 364 | 25092922 |
US |
58 | 1 |
Product dose omission issue, Product use issue, Gastrointestinal disorder, |
||||
LENALIDOMIDE, DARATUMUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ROSUVASTATIN, BORTEZOMIB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ACYCLOVIR, |
||||
| 365 | 25093220 |
IT |
2 | |
Methaemoglobinaemia, Product use in unapproved indication, Product use issue, |
||||
NITROGLYCERIN, |
||||
| 366 | 25093344 |
US |
2 | |
Frequent bowel movements, Product use issue, Product distribution issue, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, |
||||
| 367 | 25093505 |
US |
30 | 2 |
Seizure, Tardive dyskinesia, Overdose, Product use issue, |
||||
BRIVARACETAM, BRIVARACETAM, BRIVARACETAM, |
||||
| 368 | 25093546 |
US |
||
Hospitalisation, Illness, Product use issue, Product dose omission issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 369 | 25093883 |
US |
||
Cataract, Scoliosis, Gait disturbance, Wrong technique in device usage process, Wrong technique in product usage process, Product use issue, Device delivery system issue, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 370 | 25094168 |
US |
2 | |
Seizure, Cerebral disorder, Fatigue, Product use issue, |
||||
BRIVARACETAM, BRIVARACETAM, VONOPRAZAN FUMARATE, SUCRALFATE, SUCRALFATE ORAL SUSPENSION, SUCRALFATE ORAL, |
||||
| 371 | 25094356 |
US |
||
Pulmonary congestion, Overdose, Fear, Cough, Dysgeusia, Stress, Dyspnoea, Device use issue, Device delivery system issue, Device malfunction, Incorrect dose administered, Wrong technique in product usage process, Product use issue, Product dose omission issue, Histrionic personality disorder, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 372 | 25094366 |
US |
2 | |
Adverse event, Product use issue, |
||||
POLYETHYLENE GLYCOL 3350, |
||||
| 373 | 25094438 |
CA |
64 | 2 |
Malignant neoplasm progression, Pneumonitis, Product use issue, Therapy partial responder, |
||||
CAPECITABINE, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 374 | 25094472 |
US |
||
Product use issue, Macular degeneration, |
||||
| 375 | 25094786 |
US |
81 | 2 |
Product dose omission in error, Product use issue, |
||||
LENALIDOMIDE, |
||||
| 376 | 25094807 |
CA |
2 | |
Arthropathy, Contraindicated product administered, Pemphigus, Off label use, Product use issue, Rash, Wound, Systemic lupus erythematosus, Pain, Drug ineffective, Abdominal discomfort, Maternal exposure during pregnancy, Glossodynia, Fatigue, Rheumatoid arthritis, Swelling, Alopecia, Hand deformity, Intentional product use issue, Discomfort, |
||||
METHOTREXATE, METHOTREXATE SODIUM, ALENDRONATE SODIUM, RITUXIMAB, LEFLUNOMIDE, LEFLUNOMIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, CERTOLIZUMAB PEGOL, TOFACITINIB, INFLIXIMAB, INFLIXIMAB, FOLIC ACID, FOLIC ACID, METHOTREXATE, METHOTREXATE SODIUM, TOCILIZUMAB, TOCILIZUMAB, ABATACEPT, ABATACEPT, DESOXIMETASONE, DESOXIMETASONE, CORTISONE ACETATE, CORTISONE ACETATE, PREDNISONE, SULFASALAZINE, SULFASALAZINE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, ETANERCEPT, ETANERCEPT, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ADALIMUMAB, LEFLUNOMIDE, |
||||
| 377 | 25094809 |
CA |
60 | 2 |
Abdominal discomfort, Swollen joint count increased, Hypersensitivity, Treatment failure, Movement disorder, Abdominal discomfort, Pain, Arthropathy, Hypertension, Pericarditis, Product use issue, Therapeutic product effect decreased, Swelling, Joint swelling, Synovitis, Loss of personal independence in daily activities, Coeliac disease, Injection site reaction, Nail operation, Grip strength decreased, Blood cholesterol increased, Rheumatic fever, Arthralgia, Pemphigus, Onychomycosis, Fatigue, Drug ineffective, Type 2 diabetes mellitus, General physical health deterioration, Alopecia, Maternal exposure during pregnancy, Nail disorder, Condition aggravated, Systemic lupus erythematosus, Musculoskeletal stiffness, Gait disturbance, Contraindicated product administered, Onychomadesis, Headache, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, LEFLUNOMIDE, TOCILIZUMAB, TOCILIZUMAB, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, GOLIMUMAB, FOLIC ACID, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, RITUXIMAB, RITUXIMAB, CORTISONE ACETATE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, ADALIMUMAB, ADALIMUMAB, ABATACEPT, ABATACEPT, ABATACEPT, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, PREDNISONE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ETANERCEPT, ETANERCEPT, ETANERCEPT, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DESOXIMETASONE, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, ALENDRONATE SODIUM, INFLIXIMAB, |
||||
| 378 | 25094825 |
CA |
1 | 2 |
Adrenal insufficiency, Intentional product use issue, C-reactive protein abnormal, Bone density abnormal, Psoriasis, Short stature, Off label use, Product use issue, Drug ineffective, Polyarthritis, Prescribed underdose, Joint effusion, Synovitis, Red blood cell sedimentation rate abnormal, Hypocalcaemia, Septic shock, Obesity, Condition aggravated, Arthritis, Pleural effusion, Arthritis, Arthralgia, Human antichimeric antibody positive, Arthropathy, Contraindicated product administered, Drug intolerance, Therapy non-responder, Off label use, Loss of personal independence in daily activities, Gastroenteritis viral, Quality of life decreased, Liver function test abnormal, Joint destruction, Joint injury, Condition aggravated, Dizziness, Juvenile idiopathic arthritis, Off label use, Hypokalaemia, Antibody test positive, Immunodeficiency, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, TOCILIZUMAB, TOCILIZUMAB, ANAKINRA, ANAKINRA, ANAKINRA, ANAKINRA, ANAKINRA, ANAKINRA, ANAKINRA, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, TRIAMCINOLONE HEXACETONIDE, TOCILIZUMAB, TOCILIZUMAB, NAPROXEN, NAPROXEN SODIUM, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, TOFACITINIB, |
||||
| 379 | 25094954 |
TH |
79 | 1 |
Pain in extremity, Gait inability, Musculoskeletal stiffness, Fatigue, Product use issue, Hypersensitivity, Skin fissures, Dry skin, Peripheral swelling, Erythema, |
||||
REGORAFENIB, REGORAFENIB, |
||||
| 380 | 25095240 |
US |
||
Sensitive skin, Product use issue, |
||||
ADAPALENE, |
||||
| 381 | 25095241 |
US |
||
Erythema, Dry skin, Skin burning sensation, Acne, Product use issue, |
||||
ADAPALENE, GUANFACINE, GUANFACINE HYDROCHLORIDE, GAUNFACINE, METHYLPHENIDATE HYDROCHLORIDE, |
||||
| 382 | 25095335 |
DE |
61 | 2 |
Retinal detachment, Retinal tear, Intermenstrual bleeding, Gastrooesophageal reflux disease, Product use issue, |
||||
PROGESTERONE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 383 | 25095379 |
PE |
1 | |
Death, Off label use, Product use issue, |
||||
AXITINIB, PEMBROLIZUMAB, |
||||
| 384 | 25096011 |
CA |
1 | |
Fear of injection, Hepatic iron overload, Sickle cell anaemia, Iron overload, Product use issue, |
||||
DEFERASIROX, DEFERASIROX, DEFEROXAMINE MESYLATE, |
||||
| 385 | 25096032 |
US |
||
Product use issue, |
||||
NITISINONE, NITISINONE, |
||||
| 386 | 25096244 |
US |
72 | 1 |
Incorrect dose administered, Product dose omission issue, Product use issue, Inability to afford medication, |
||||
DEUTETRABENAZINE, DEUTETRABENAZINE, DEUTETRABENAZINE, DEUTETRABENAZINE, |
||||
| 387 | 25096706 |
US |
54 | 2 |
Product use issue, |
||||
OZANIMOD HYDROCHLORIDE, |
||||
| 388 | 25096739 |
US |
1 | |
Brain oedema, Ear pain, Headache, Incorrect dose administered, Product use issue, |
||||
BRIVARACETAM, LEVETIRACETAM, |
||||
| 389 | 25097123 |
US |
2 | |
Pregnancy with implant contraceptive, Unintended pregnancy, Product use issue, |
||||
ETONOGESTREL, |
||||
| 390 | 25097137 |
US |
55 | 1 |
Hereditary angioedema, Product use issue, |
||||
| 391 | 25086727 |
US |
2 | |
Death, Product use issue, |
||||
PRUCALOPRIDE, |
||||
| 392 | 25086747 |
MX |
52 | 2 |
Near death experience, Malaise, Hypertension, Weight increased, Nausea, Abdominal pain upper, Blood glucose increased, Product use issue, |
||||
ORAL SEMAGLUTIDE, ORAL SEMAGLUTIDE, LIRAGLUTIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ENALAPRIL, LINAGLIPTIN, ERGOCALCIFEROL, |
||||
| 393 | 25086915 |
DE |
41 | 1 |
Neuropathy peripheral, Paraesthesia, Allodynia, Product use issue, |
||||
SEMAGLUTIDE, |
||||
| 394 | 25086935 |
US |
90 | 2 |
Headache, Product use issue, Product use issue, Product use issue, Circumstance or information capable of leading to device use error, |
||||
FREMANEZUMAB-VFRM, |
||||
| 395 | 25087018 |
MY |
2 | |
Cytopenia, Blood pressure increased, Rash, Transaminases increased, Off label use, Product use issue, |
||||
GILTERITINIB, AZACITIDINE, AZACITIDINE FOR, |
||||
| 396 | 25087030 |
US |
73 | 2 |
Pneumonia, White blood cell count decreased, Feeling abnormal, Pallor, Motion sickness, Haemoglobin decreased, Fatigue, Headache, Eye disorder, Weight decreased, Influenza, Product packaging difficult to open, Product use issue, Diarrhoea, |
||||
IXAZOMIB, LENALIDOMIDE, ACYCLOVIR, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, DIPHENHYDRAMINE HYDROCHLORIDE, OIL, BIOTIN, HAIR, LISINOPRIL, IBUPROFEN, ERGOCALCIFEROL, |
||||
| 397 | 25087073 |
US |
2 | |
Intentional product use issue, Product use issue, Product availability issue, |
||||
CROMOLYN SODIUM, |
||||
| 398 | 25087145 |
US |
2 | |
Drug hypersensitivity, Product dose omission issue, Product use issue, |
||||
ECALLANTIDE, ECALLANTIDE, |
||||
| 399 | 25087266 |
CA |
44 | 2 |
Breast cancer stage III, Depression, Therapy non-responder, Vomiting, Hand deformity, Arthralgia, Abdominal pain, Contraindicated product administered, Liver injury, Memory impairment, Prescribed overdose, Delirium, Wound infection, Pain, Dizziness, Alopecia, Treatment noncompliance, Mobility decreased, Pericarditis, Glossodynia, Product use issue, Musculoskeletal stiffness, Live birth, Grip strength decreased, Treatment failure, Nausea, Fatigue, Rheumatoid arthritis, Pemphigus, Weight decreased, Drug intolerance, Duodenal ulcer perforation, Systemic lupus erythematosus, Sleep disorder, Psoriatic arthropathy, Dyspnoea, Psoriasis, Helicobacter infection, Hypertension, Condition aggravated, Rheumatic fever, Malaise, Dislocation of vertebra, Oedema, Hypersensitivity, Fibromyalgia, Blood cholesterol increased, Joint swelling, Blister, Abdominal discomfort, Amnesia, Swelling, Drug hypersensitivity, Disability, Diarrhoea, Swollen joint count increased, Synovitis, Infusion related reaction, Chest pain, General physical health deterioration, Intentional product use issue, Maternal exposure during pregnancy, Exposure during pregnancy, Anxiety, Wheezing, Rheumatoid factor positive, Infection, Decreased appetite, Rash, Adjustment disorder with depressed mood, Muscular weakness, Adverse event, Injury, Drug ineffective, Type 2 diabetes mellitus, Arthropathy, Gait disturbance, Headache, Anti-cyclic citrullinated peptide antibody positive, Hypoaesthesia, Discomfort, Joint range of motion decreased, Abdominal pain upper, Walking aid user, Hepatic enzyme increased, Adverse drug reaction, Therapeutic product effect decreased, Wound, Off label use, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHYLPREDNISOLONE SODIUM SUCCINATE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, CELECOXIB, CELECOXIB, VEDOLIZUMAB, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, MAGNESIUM, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, SARILUMAB, APREPITANT, APREPITANT, APREPITANT, APREPITANT, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, CALCIUM CARBONATE, ANTACID, SULFASALAZINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, RAMIPRIL, TOFACITINIB, TOFACITINIB, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, CALCIUM, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, APREMILAST, APREMILAST, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, PREDNISONE, NAPROXEN, NAPROXEN SODIUM, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, CERTOLIZUMAB PEGOL, CALCIUM GLUCONATE, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, SECUKINUMAB, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, APREMILAST, NAPROXEN SODIUM, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, NAPROXEN SODIUM, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, LEFLUNOMIDE, LEFLUNOMIDE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, LISINOPRIL, GOLIMUMAB, GOLIMUMAB, VITAMIN C, |
||||
| 400 | 25087301 |
CA |
43 | 2 |
Exposure during pregnancy, Laryngitis, Live birth, Liver function test increased, Liver injury, Lower limb fracture, Lupus-like syndrome, Lupus vulgaris, Maternal exposure during pregnancy, Memory impairment, Mobility decreased, Infusion related reaction, Muscle injury, Muscular weakness, Musculoskeletal stiffness, Nasopharyngitis, Nausea, Oedema, Oedema peripheral, Osteoarthritis, Osteoporosis, Injury, Pain, Pain in extremity, Pemphigus, Pericarditis, Peripheral swelling, Pneumonia, Pruritus, Psoriasis, Psoriatic arthropathy, Pulmonary fibrosis, Pyrexia, Rash, Red blood cell sedimentation rate increased, Retinitis, Rheumatic fever, Irritable bowel syndrome, Joint dislocation, Joint range of motion decreased, Joint stiffness, Joint swelling, Prescribed underdose, Prescribed overdose, Product use issue, Intentional product use issue, Product use in unapproved indication, Off label use, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ERENUMAB-AOOE, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, OXYCODONE, OXYCODONE, OXYCODONE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28